| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/17/2006 | CA2597557A1 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
| 08/17/2006 | CA2597541A1 Crystal of 4(3h)-quinazolinone derivative |
| 08/17/2006 | CA2597537A1 Ointment |
| 08/17/2006 | CA2597523A1 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated withcytotoxicity in general and apoptosis in particular |
| 08/17/2006 | CA2597492A1 A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor |
| 08/17/2006 | CA2597481A1 Ligands for g-protein coupled receptors |
| 08/17/2006 | CA2597447A1 Novel tubulin polymerisation inhibitors |
| 08/17/2006 | CA2597408A1 Substituted propane phosphinic acid esters |
| 08/17/2006 | CA2597402A1 A capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom |
| 08/17/2006 | CA2597397A1 Treatment for topical use in alleviating or inhibiting joint pain or muscle pain or musculoskeletal pain in a mammal |
| 08/17/2006 | CA2597395A1 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| 08/17/2006 | CA2597384A1 Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases |
| 08/17/2006 | CA2597350A1 Process for purifying noroxymorphone compounds |
| 08/17/2006 | CA2597339A1 Use of silymarine and/or the constituents thereof as promoters of the pigmentation of the skin or hair |
| 08/17/2006 | CA2597332A1 Methods for improving drug disposition |
| 08/17/2006 | CA2597329A1 Compositions and methods involving mda-7 for the treatment of cancer |
| 08/17/2006 | CA2597324A1 Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| 08/17/2006 | CA2597288A1 Dihydroimidazothiazole derivatives |
| 08/17/2006 | CA2597273A1 Proteasome inhibitors and methods of using the same |
| 08/17/2006 | CA2597257A1 Production of polyunsaturated fatty acids using novel cell treatment method |
| 08/17/2006 | CA2597101A1 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency |
| 08/17/2006 | CA2597087A1 Diamine calcium channel blockers |
| 08/17/2006 | CA2597073A1 Glucagon receptor antagonists, preparation and therapeutic uses |
| 08/17/2006 | CA2597055A1 A catheter lock solution comprising citrate and a paraben |
| 08/17/2006 | CA2597016A1 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine |
| 08/17/2006 | CA2596876A1 Method for the mitigation of symptoms of contact lens related dry eye |
| 08/17/2006 | CA2596822A1 Substituted pyrroles, compositions containing same, method for making same and use thereof |
| 08/17/2006 | CA2596755A1 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
| 08/17/2006 | CA2596613A1 Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, thiourea and urea) as cannabinoid cb1 receptor antagonists |
| 08/17/2006 | CA2596506A1 Antisense composition and method for treating muscle atrophy |
| 08/17/2006 | CA2596501A1 Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| 08/17/2006 | CA2596485A1 Combination of organic compounds |
| 08/17/2006 | CA2596422A1 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy |
| 08/17/2006 | CA2596407A1 Methods for treating parkinson's disease |
| 08/17/2006 | CA2596202A1 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| 08/17/2006 | CA2595766A1 Cci-779 polymorph and use thereof |
| 08/17/2006 | CA2595635A1 Methods of making pravastatin sodium |
| 08/17/2006 | CA2595633A1 Synthetic sealants |
| 08/17/2006 | CA2595495A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 08/17/2006 | CA2594662A1 Mitotic kinesin inhibitors |
| 08/17/2006 | CA2594657A1 Inhibitors of checkpoint kinases |
| 08/17/2006 | CA2594542A1 Synthesis of inhibitors of p90rsk |
| 08/17/2006 | CA2594415A1 Device for treatment of disorders in the oral cavity with nitric oxide, and manufacturing process for the same |
| 08/17/2006 | CA2594407A1 Device method, and use for treatment of neuropathy involving nitric oxide |
| 08/17/2006 | CA2594395A1 Hiv protease inhibitors |
| 08/17/2006 | CA2593497A1 Amorphous ziprasidone mesylate |
| 08/17/2006 | CA2592941A1 Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors |
| 08/17/2006 | CA2580882A1 Antibiotic compound |
| 08/17/2006 | CA2576425A1 Compositions and methods for treating or preventing hepadnaviridae infection |
| 08/17/2006 | CA2570577A1 Anti-viral uses of borinic acid complexes |
| 08/17/2006 | CA2563109A1 Anti-hiv quinuclidine compounds |
| 08/16/2006 | EP1690875A1 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype |
| 08/16/2006 | EP1690864A2 Tricyclic purine compounds and their analogs as inhibitors of cytokine signalling |
| 08/16/2006 | EP1690863A1 Novel condensed imidazole derivative |
| 08/16/2006 | EP1690861A2 A process for preparing duloxetine and intermediates for use therein |
| 08/16/2006 | EP1690858A1 Monohydrochloride salt of 1-¬3-¬3-(4-chlorophenyl)propoxy|propyl|-piperidine |
| 08/16/2006 | EP1690857A1 Modified-protein formation inhibitor |
| 08/16/2006 | EP1690854A1 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 08/16/2006 | EP1690853A1 W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 08/16/2006 | EP1690852A1 Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto |
| 08/16/2006 | EP1690558A1 Device for treatment of diabetic disorders |
| 08/16/2006 | EP1690557A1 Device for treatment of rectal disorders, and manufacturing process for the same |
| 08/16/2006 | EP1690545A2 A combination therapy for HIV infections |
| 08/16/2006 | EP1690544A2 Pharmaceutical composition containing decoy and method of using the same |
| 08/16/2006 | EP1690543A1 Pharmaceutical composition for contraception |
| 08/16/2006 | EP1690542A2 Pharmaceutical composition for the treatment of ovarian cancer |
| 08/16/2006 | EP1690541A1 Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency |
| 08/16/2006 | EP1690540A1 Composition comprising ocaperidone |
| 08/16/2006 | EP1690539A2 Salts of tiotropium for treating inflammatory disorders |
| 08/16/2006 | EP1690538A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor |
| 08/16/2006 | EP1690537A1 Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia |
| 08/16/2006 | EP1690536A2 Use of r-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methyl-phenylisobutyric acid ester hydrogenfumarate for the treatment of urinary incontinence and other spasmogenic disorders |
| 08/16/2006 | EP1690535A2 Therapeutic use of nitric oxide precursor |
| 08/16/2006 | EP1690534A2 Lipoic acid in topical compositions |
| 08/16/2006 | EP1690533A1 Composition having liver function protective effect |
| 08/16/2006 | EP1690457A1 Package drink |
| 08/16/2006 | EP1689888A2 Detection of mutations in a gene associated with resistance to viral infection, oas1 |
| 08/16/2006 | EP1689880A1 Detection of no by using guanylyl cyclase and cgmp production as a readout system |
| 08/16/2006 | EP1689874A1 Method for the production of a compound, comprising a free hydroxyl group and a hydroxyl group which is protected by an ester function by enzymatic reaction |
| 08/16/2006 | EP1689864A2 Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions |
| 08/16/2006 | EP1689795A1 Method of manufacture of polyacrolein |
| 08/16/2006 | EP1689770A1 Depeptidized inhibitors of hepatitis c virus ns3 protease |
| 08/16/2006 | EP1689768A2 Estrogen receptor modulators |
| 08/16/2006 | EP1689767A1 Estrogen receptor modulators |
| 08/16/2006 | EP1689759A1 Method for producing pure disodium pamidronate |
| 08/16/2006 | EP1689758A2 New class of gamma delta t cells activators and use thereof |
| 08/16/2006 | EP1689757A1 Heterocyclic boronic acid compounds |
| 08/16/2006 | EP1689754A1 42-o-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| 08/16/2006 | EP1689753A1 Novel chemical compounds |
| 08/16/2006 | EP1689752A1 Pyrazolopyrimidines |
| 08/16/2006 | EP1689751A1 5,7-diaminopyrazolo¬4,3-d|pyrimidines with pde-5 inhibiting activity |
| 08/16/2006 | EP1689750A1 6-(2,4,6-trifluorophenyl)-triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungi, and substances containing the same |
| 08/16/2006 | EP1689748A1 Novel 8-(piperazine-1-yl)- and 8-( 1,4|diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug |
| 08/16/2006 | EP1689747A1 1h-imidazo [4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
| 08/16/2006 | EP1689745A1 Novel macrocycles for treating tumor diseases |
| 08/16/2006 | EP1689744A1 Antiresorptive mutual salt of raloxifene and bisphosphonic acid |
| 08/16/2006 | EP1689743A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 08/16/2006 | EP1689742A1 Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| 08/16/2006 | EP1689741A1 Benzoyl amino pyridyl carboxylic acid derivatives as glucokinase activators |
| 08/16/2006 | EP1689740A1 Pyrazolyl and imidazolyl pyrimidines |